Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients

Kristine Hole¹ | Petra L. Heiberg¹ | Caroline Gjestad¹ | Lise L. Mehus² | Øyvind Rø³,⁴ | Espen Molden¹,⁵

1Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
2Department of Medicinal Biochemistry, Diakonhjemmet Hospital, Oslo, Norway
3Regional Department for Eating Disorders, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
4Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
5Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway

Correspondence
Kristine Hole, Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
Email: kristine.hole@diakonsyk.no

Abstract
Recent studies have shown that the cytochrome P450 (CYP) 3A phenotype marker 4β-hydroxycholesterol/cholesterol (4βOHC/C) ratio is negatively correlated with body weight in healthy volunteers, and that obese patients have lower 4βOHC levels than healthy controls. However, 4βOHC/C ratio in underweight patients has yet to be reported. The aim of this study was to examine potential differences in CYP3A activity between underweight patients with anorexia nervosa and normal-weight volunteers by measuring plasma 4βOHC/C ratio. Furthermore, we wished to describe any association between body mass index (BMI) and 4βOHC/C ratio in underweight patients. A total of 20 underweight patients and 16 normal-weight volunteers were included in the study, all females. Underweight patients had a median 4βOHC/C ratio (molar ratio × 10⁻⁵) of 2.52 (range, 0.90–11.3) compared to 1.29 (0.56–2.09) in normal-weight subjects (Mann-Whitney P = 0.0005). 4βOHC/C ratio was negatively correlated with BMI in underweight patients (r = −0.56, P = 0.011), and in the whole study population (r = −0.67, P < 0.0001). This suggests that the negative correlation between 4βOHC/C and BMI, which has previously been reported between 4βOHC/C and body weight in healthy volunteers, extends to underweight patients. The findings indicate that CYP3A activity increases with decreasing BMI, resulting in higher CYP3A activity in underweight patients compared to normal-weight subjects. The potential clinical relevance of this needs to be studied further by comparing pharmacokinetics of drugs subjected to CYP3A-mediated metabolism in underweight vs. normal-weight individuals.

KEYWORDS
4β-hydroxycholesterol, anorexia nervosa, BMI, CYP3A

INTRODUCTION
Cytochrome P450 (CYP) 3A enzymes play a major role in the metabolism of about 30% of clinically used drugs.⁰ Substantial...
inter-individual variability in CYP3A activity exists due to a combination of genetic, environmental, and endogenous factors. CYP3A phenotype can be measured by the endogenous biomarker 4β-hydroxycholesterol (4βOHC), which is metabolized from cholesterol by CYP3A4 and CYP3A5, the two most important CYP3A enzymes in humans. Variations in cholesterol concentration have been found to explain about 10% of 4βOHC variation, and 4βOHC/cholesterol (4βOHC/C) ratio is preferable to 4βOHC as CYP3A biomarker in patient groups where cholesterol levels are abnormal.

Recent studies have shown that body weight is negatively correlated with 4βOHC/C ratio in healthy volunteers, and that obese patients have lower 4βOHC levels than healthy controls. Studies on the clearance of a number of other CYP3A substrates suggest that CYP3A activity is reduced by 10-35% in obese patients. Furthermore, Ulvestad et al. reported strong negative correlation between body mass index (BMI) and CYP3A protein expression in liver and intestines. Altogether, this indicates that CYP3A activity decreases with increasing body weight. However, 4βOHC/C ratio in underweight patients is yet to be reported, and it is not known whether the correlation between BMI and CYP3A activity extends to underweight patients.

The aim of our study was to examine potential differences in CYP3A activity between underweight patients with anorexia nervosa and normal-weight volunteers by measuring plasma 4βOHC/C ratio. Furthermore, we wished to describe any association between BMI and 4βOHC/C ratio in underweight patients.

2 | MATERIALS AND METHODS

2.1 | Subjects

Patients with severe anorexia nervosa (n = 20) were included from an inpatient unit at the Regional Department for Eating Disorders, Division of Mental Health and Addiction, Oslo University Hospital, Norway, from May 2012 to September 2013. Inclusion criteria were (i) anorexia nervosa diagnosis according to DSM-IV; (ii) female sex; and (iii) BMI < 18.5. Normal-weight control subjects (n = 16) were recruited from School of Pharmacy, University of Oslo, Norway in May 2016. Inclusion criteria for normal-weight volunteers were (i) female sex; and (ii) BMI ≥ 18.5.

All subjects gave written, informed consent. The study was approved by the Regional Committee for Medical and Health Research Ethics South-East.

2.2 | 4βOHC analyses

Plasma concentration of 4βOHC was determined by a previously described UPLC-MS/MS assay. The lower limit of quantification was 10 ng/mL. Intra- and inter-day imprecision and inaccuracy for the method were <15% at 10 ng/mL and <4% at 644 ng/mL (n = 6). All samples were stored at −80°C between sampling and analysis. For the underweight patient samples, stability of 4βOHC during storage was ensured by controlling that 4αOHC concentration was lower than 4βOHC concentration. This was not done for normal weight samples, since they were analyzed only 5 months after sampling; within the time frame that 4βOHC is known to maintain stability.

2.3 | Endpoints and statistical analyses

BMI was calculated as body weight divided by height squared (kg/m²). 4βOHC/C ratio was calculated as 4βOHC concentration (mmol/L) divided by total cholesterol concentration (mmol × 10⁹/L). Mann-Whitney U tests were used for comparisons of 4βOHC/C ratio and other characteristics between anorexia nervosa patients and normal-weight subjects. Spearman correlation was used to evaluate association between BMI and 4βOHC/C ratio and between 4βOHC and cholesterol. Statistical significance was considered as P < 0.05. GraphPad Prism for Windows, version 6.01 (GraphPad Software, La Jolla, CA), was used for statistical analyses and graphical presentations.

3 | RESULTS

Clinical and demographic characteristics of included subjects are listed in Table 1. All included subjects were female, and there were no differences in age or total cholesterol between the two groups (P > 0.1). None of the included subjects used CYP3A inducers according to the Flockhart CYP Drug Interaction Table. One of the anorexia nervosa patients used fluoxetine, a CYP3A inhibitor. The patient was not excluded since results showed higher 4βOHC concentration in underweight patients compared to normal-weight subjects. All drugs used by included subjects are listed in Table 2.

The association between 4βOHC and cholesterol concentration in the whole study population was significant (r = 0.41, P = 0.013). The median 4βOHC concentration in underweight patients was 49.0 ng/mL (range, 18.5–129 ng/mL) compared to 22.0 ng/mL (10.8–41.9 ng/mL) in normal-weight subjects (P < 0.0001) (Figure 1A). Underweight patients had a median 4βOHC/C ratio (molar ratio × 10⁻⁵) of 2.52 (0.90–11.3) compared to 1.29 (0.56–2.09) in normal-weight subjects (P = .0005) (Figure 1B). 4βOHC/C ratio was

| TABLE 1  Clinical and demographic characteristics |
|-----------------------------------------------|
| Variables          | Anorexia nervosa (n = 20) | Normal-weight (n = 16) | P value |
| Age, years         | 24 (15-47)                 | 23 (19-48)              | 0.81    |
| Body weight, kg    | 43 (29-53)                 | 61 (43-77)              | <0.0001 |
| Body mass index, kg/m² | 14.9 (10.1-18.0)     | 21.5 (19.4-25.2)         | <0.0001 |
| Total cholesterol, mmol/L | 5.07 (2.83-6.88) | 4.54 (3.44-5.80)          | 0.12    |

Data are expressed as median (range), and P values are derived from Mann-Whitney U tests.
TABLE 2 Overview of drugs used by included subjects

| Drugs              | Anorexia nervosa patients | Normal-weight subjects |
|--------------------|---------------------------|------------------------|
|                    | Number of patients        | Drugs                  | Number of subjects |
| Alimemazine        | 1                         | Cetirizine             | 2                     |
| Chlorpromethine    | 1                         | Combination contraceptives | 5                   |
| Desloratadine      | 1                         | Desloratadine          | 2                     |
| Fluoxetine         | 1                         | Levotyroline           | 2                     |
| Levotyroline       | 1                         | Naproxen               | 1                     |
| Melatonin          | 1                         | Paracetamol            | 1                     |
| Metoprolol         | 1                         | Progesterone only      | 6                     |
| Promethazine       | 1                         | Valerian root          | 1                     |
| Quetiapine         | 1                         |                        |                       |

negatively correlated with BMI in underweight patients ($r = -0.56$, $P = 0.011$) (Figure 2A), and in the whole study population ($r = -0.67$, $P < 0.0001$) (Figure 2B).

4 | DISCUSSION

We found that the underweight patients had twice the plasma 4\(\beta\)OHC/C ratio of normal-weight volunteers. Furthermore, 4\(\beta\)OHC/C ratio was strongly correlated with BMI in the whole population regardless of the participants’ status as underweight or normal-weight. This suggests that the negative correlation between 4\(\beta\)OHC/C and BMI, which has previously been reported between 4\(\beta\)OHC/C and body weight in healthy volunteers, extends to underweight patients. The findings indicate that CYP3A activity increases with decreasing BMI, resulting in higher CYP3A activity in underweight patients compared to normal-weight subjects. However, this needs to be studied further with other CYP3A substrates in underweight vs. normal-weight individuals.

Studies evaluating CYP3A metabolism in anorexia nervosa patients are scarce. Boyar et al. reported reduced clearance of cortisol, a partial CYP3A substrate, in anorexia nervosa patients compared to healthy subjects. Cachectic patients have been reported to have both increased and decreased CYP3A metabolism, but not to have altered liver content of CYP3A proteins. Altogether, conflicting reports make it difficult to conclude whether CYP3A metabolism in underweight patients diverges from normal-weight subjects.

In this study, we report that anorexia nervosa patients have higher 4\(\beta\)OHC concentration and 4\(\beta\)OHC/C ratio compared to normal-weight volunteers, and hypothesize that this reflects elevated CYP3A activity in underweight patients. Anorexia nervosa patients often have hypercholesterolemia. Hyperadiponectinemia is known to occur in anorexic patients, and may be related to increased cholesterol synthesis. To account for impact of altered cholesterol levels on 4\(\beta\)OHC concentration, we consider 4\(\beta\)OHC/C ratio to be a more appropriate CYP3A biomarker in this study population. However, whether using 4\(\beta\)OHC concentration or 4\(\beta\)OHC/C ratio, we report approximately twice the biomarker level in underweight patients compared to normal-weight volunteers. The normal-weight volunteers had 4\(\beta\)OHC levels and 4\(\beta\)OHC/C ratio within the normal range. Obesity has been associated with reduced plasma 4\(\beta\)OHC levels, and hence emaciation could lead to increased 4\(\beta\)OHC levels. However, distorted 4\(\beta\)OHC levels could be caused by changes both in production and elimination, and 4\(\beta\)OHC is further metabolized via CYP7A1 and CYP27A1. Reduced 4\(\beta\)OHC and elevated plasma 27OHC levels have been reported in an obese mouse model, which could indicate that obesity is associated with increased CYP27A1 activity and therefore increased elimination of 4\(\beta\)OHC. However, Ulvestad et al. reported strong negative correlation between BMI and both hepatic and small-intestinal CYP3A protein expression in obese patients, supporting our findings that CYP3A activity is correlated with BMI.

Theoretically, reduced tissue distribution of 4\(\beta\)OHC and/or increased lipolysis may result in increased 4\(\beta\)OHC/C ratio in anorexia nervosa patients. Thus, it cannot be ruled out that increased 4\(\beta\)OHC/C ratio might be caused by other factors than increased CYP3A activity in this underweight population. However, due to the strong correlation between BMI and 4\(\beta\)OHC/C ratio in the whole study population, including both underweight and normal-weight subjects, we find it likely that the increased 4\(\beta\)OHC/C ratio reflects an increase of CYP3A activity.

A limitation of the present study is that only one CYP3A biomarker was tested. Unfortunately, no probe drug such as midazolam was given to the participants at the time of the study. Thus, additional studies with other CYP3A substrates are necessary to confirm our results. Genotyping of CYP3A4 and CYP3A5 would also have been of interest. Expression of the CYP3A5*1 allele has been

![Figure 1](image-url)
associated with elevated 4βOHC levels, although a larger study did not find any association between 4βOHC levels and CYP3A5*3 or CYP3A4*22 polymorphisms. Other potential sources of inter-individual variation in 4βOHC levels are ethnicity and inflammation.

An advantage with 4βOHC as biomarker is its selectivity; CYP3A4 and CYP3A5 convert cholesterol to 4βOHC, while only negligible amounts of 4βOHC were produced by seven other CYP enzymes. Furthermore, 4βOHC has an unusually long half-life of up to 17 days, which leads to low intra-individual variability. Since 4βOHC is sensitive to CYP3A induction, we consider it a suitable biomarker for the present study where anorexic patients displayed elevated 4βOHC levels.

In conclusion, we report that anorexia nervosa patients have twice the plasma 4βOHC/C ratio of normal-weight volunteers, and that 4βOHC/C ratio has a strong negative correlation with BMI. The findings indicate that CYP3A activity increases with decreasing BMI, resulting in higher CYP3A activity in underweight patients compared to normal-weight subjects. However, the potential clinical relevance needs to be studied further by comparing pharmacokinetics of drugs subjected to CYP3A-mediated metabolism in underweight vs. normal-weight individuals.

**AUTHOR CONTRIBUTIONS**

Participated in research design: Hole, Heiberg, Molden. Contributed to acquisition of data: Hole, Heiberg, Gjestad, Mehus, Re, Molden. Performed data analysis: Hole. Wrote or contributed to the writing of the manuscript: Hole, Heiberg, Gjestad, Mehus, Re, Molden.

**DISCLOSURE**

None declared.

**ORCID**

Kristine Hole  http://orcid.org/0000-0001-7300-5329

**REFERENCES**

1. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103-141.

2. Hole K, Gjestad C, Heitmann KM, Haslemo T, Molden E, Bremer S. Impact of genetic and nongenetic factors on interindividual variability in 4beta-hydroxycholesterol concentration. Eur J Clin Pharmacol. 2017;73:317-324.

3. Bodin K, Andersson U, Rystedt E, et al. Metabolism of 4 beta-hydroxycholesterol in humans. J Biol Chem. 2002;277:31534-31540.

4. Nitta SI, Hashimoto M, Kazuki Y, et al. Evaluation of 4beta-hydroxycholesterol and 25-hydroxycholesterol as endogenous biomarkers of CYP3A4: study with CYP3A-humanized mice. AAPS J. 2018;20:61.

5. Diczfalusy U, Miura J, Roh HK, et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics. 2008;18:201-208.

6. Bjorkhem-Bergman L, Nylen H, Eriksson M, Parini P, Diczfalusy U. Effect of statin treatment on plasma 4beta-hydroxycholesterol concentrations. Basic Clin Pharmacol Toxicol. 2016;118:499-502.

7. Woolsey SJ, Beaton MD, Choi YH, et al. Relationships between endogenous plasma biomarkers of constitutive cytochrome P450 3A activity and single-time-point oral midazolam microdose phenotype in healthy subjects. Basic Clin Pharmacol Toxicol. 2016;118:284-291.

8. Tremblay-Franco M, Zerbinati C, Pacelli A, et al. Effect of obesity and metabolic syndrome on plasma oxysterols and fatty acids in human. Steroids. 2015;99:287-292.

9. Kotliar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther. 1999;37:8-19.

10. Ulvestad M, Skottheim IB, Jakobsen GS, et al. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther. 2013;93:275-282.

11. Gjestad C, Huynh DK, Haslemo T, Molden E. 4beta-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? Br J Clin Pharmacol. 2016;81:269-276.

12. Starset E, Hole K, Midveldt K, Bergan S, Molden E, Åsberg A. The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. Br J Clin Pharmacol. 2017;83:1457-1465.

13. Aubry AF, Dean B, Diczfalusy U, et al. Recommendations on the development of a bioanalytical assay for 4beta-hydroxycholesterol, an emerging endogenous biomarker of CYP3A activity. AAPS J. 2016;18:1056-1066.

14. Diczfalusy U, Nylen H, Elander P, Bertilsson L. 4beta-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol. 2011;71:183-189.

15. Fleckhart D. Drug Interactions: Cytochrome P450 Drug Interaction Table. [Indiana University School of Medicine Web site]. 2016. www.medicine.iupui.edu/CLINPHARM/ddis/main-table. Accessed May 28, 2018.

16. Boyar RM, Hellman LD, Roffwarg H, et al. Cortisol secretion and metabolism in anorexia nervosa. N Engl J Med. 1977;296:190-193.

17. Andreassen TN, Klepstad P, Davies A, et al. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study
in 439 adult cancer patients. Eur J Clin Pharmacol. 2011;67:493-506.

18. Naito T, Tashiro M, Yamamoto K, Ohnishi K, Kagawa Y, Kawakami J. Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients. Eur J Clin Pharmacol. 2012;68:1411-1418.

19. George J, Byth K, Farrell GC. Influence of clinicopathological variables on CYP protein expression in human liver. J Gastroenterol Hepatol. 1996;11:33-39.

20. Winston AP. The clinical biochemistry of anorexia nervosa. Ann Clin Biochem. 2012;49:132-143.

21. Delporte ML, Brichard SM, Hermans MP, Beguin C, Lambert M. Hyperadiponectinaemia in anorexia nervosa. Clin Endocrinol. 2003;58:22-29.

22. Li Y, Qin G, Liu J, Mao L, Zhang Z, Shang J. Adipose tissue regulates hepatic cholesterol metabolism via adiponectin. Life Sci. 2014;118:27-33.

23. Tomalik-Scharte D, Lutjohann D, Doroshynko O, Frank D, Jetter A, Fuhr U. Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clin Pharmacol Ther. 2009;86:147-153.

24. Guillemot-Legris O, Mutemberezi V, Cani PD, Muccioli GG. Obesity is associated with changes in oxysterol metabolism and levels in mice liver, hypothalamus, adipose tissue and plasma. Sci Rep. 2016;6:19694.

25. Suzuki Y, Itoh H, Fujioka T, et al. Association of plasma concentration of 4beta-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. Drug Metab Dispos. 2014;42:105-110.

26. Bjorkhem-Bergman L, Nylen H, Norlin AC, et al. Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4beta-hydroxycholesterol in a high-dose vitamin D supplementation study. Drug Metab Dispos. 2013;41:704-708.

27. Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Bottiger Y, Bertilsson L. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol. 2009;67:38-43.

How to cite this article: Hole K, Heiberg PL, Gjestad C, Mehus LL, Rø Ø, Molden E. Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients. Pharmacol Res Perspect. 2018;e430. https://doi.org/10.1002/prp2.430